Changes in Liver Stiffness and Non-Invasive Fibrosis Scores
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to assess changes in non-invasive liver fibrosis measurements after chronic hepatitis C (HCV) eradication by direct-acting antivirals (DAA) in Egyptian adolescents.

Liver stiffness measurement (LSM), by vibration-controlled transient elastography and non-invasive fibrosis scores (FIB-4, APRI), was obtained before and 12 months after eradication with ledipasvir-sofosbuvir. The primary outcome was more than 30% decrease in LSM with resulting fibrosis stage regression for initial fibrosis more than F2 and non-progression of F0-1, using Ishak score (F0-F6). The secondary outcome was change in non-invasive fibrosis scores post-treatment.

Results:
--Analyzing 85 patients, the median baseline LSM was 5.8 and at follow-up 5.1, (73%) met the primary outcome; (19%) regression and (54%) non-progression of LSM.
--Of 18 with initial fibrosis more than F2; 13 regressed to F0-1 and 2 from F6 to F5, 1 unchanged F3, 1 increased to F3 and 1 to F4.
--Among 67 with baseline fibrosis F0-F1, 62 were unchanged and 5 increased; 4 to F2 and 1 to F3. Although (27%) had more than 30% LSM increase, only (8%), with associated comorbidities (4 -beta thalassemia, 3 hepatic steatosis), had increased fibrosis stage.
--The median baseline FIB-4 and APRI scores were 0.34 and 0.35, while at follow-up 0.3 and 0.2 respectively.

Conclusively, HCV eradication by DAA in Egyptian adolescents was associated with non-progression or regression of liver fibrosis, by non-invasive fibrosis measurements, 12-months post-treatment in the majority of cases.

Source: https://www.jpeds.com/article/S0022-3476(20)31513-4/fulltext?rss=yes
Like
Comment
Share